Key Highlights
- Scancell agreed an all-share Merger with Nasdaq-listed Neuphoria Therapeutics alongside financing worth up to $89 million.
- The deal follows FDA Fast Track Designation for lead candidate iSCIB1+, granted 28 April 2026.
- Phase 2 SCOPE trial data showed 77% progression-free survival at 20 months, versus 43% for checkpoint inhibitors alone.
- The enlarged group intends a Nasdaq Level III listing under ticker SCLT, alongside its existing AIM Quotation .
- Completion is expected late Q4 2026, subject to Shareholder votes and other closing conditions.
Weeks after winning FDA Fast Track status for its lead melanoma Vaccine , LSE-listed Scancell has agreed an all-share Reverse merger with Nasdaq-listed Neuphoria Therapeutics, paired with an $89 million financing package to fund a pivotal Phase 3 trial.
Scancell Holdings (LSE:SCLP), the Nottingham-based immuno-oncology developer, has spent 2026 stacking up regulatory wins for its lead cancer vaccine candidate. Now it has moved to translate that momentum into cash and a US listing. On 23 July 2026 the AIM company announced an all-share merger agreement with Nasdaq-listed Neuphoria Therapeutics Inc, alongside financing worth up to $89 million. The deal follows FDA Fast Track designation for Scancell's lead candidate, iSCIB1+, granted 28 April 2026, and gives the company a route to Nasdaq as it prepares a registrational Phase 3 trial in advanced melanoma.
What Happened
Under the terms disclosed, Scancell will acquire Neuphoria in an all-share deal: each Neuphoria share converts into 37.77199 Scancell ADSs plus contingent value rights tied to milestones on Neuphoria's existing Assets . Before new financing, Scancell shareholders would hold approximately 85.5% of the combined group and Neuphoria shareholders around 14.5%; after the fundraise, Scancell's share rises to roughly 86.3% of ordinary shares and 88.9% of total Capital .
The attached financing totals up to $89 million: a $39.1 million private Placement , a $12.0 million UK placing, a retail offer of up to $3.0 million, up to $25 million of Debt under a BlackRock term sheet, and a minimum $10 million of Neuphoria's own cash. New shares are priced at $0.1205 each, or 9 pence. The enlarged group intends a Nasdaq Level III listing under ticker SCLT, alongside its AIM quotation. Completion is expected late Q4 2026, subject to shareholder votes.
CEO Dr Phil L'Huillier said the deal "enables access to US investors and the broader US life sciences sector for the capital we need." Neuphoria chairman Alan Fisher said it gives his stockholders "a compelling opportunity to participate in the future value creation" of Scancell's pipeline while keeping upside in Neuphoria's own programmes via the CVRs.
Why It Matters
The mechanics matter as much as the headline. Neuphoria is focused on neuropsychiatric disorders, with lead candidate BNC210 targeting anxiety-related conditions — no scientific overlap with Scancell's cancer vaccines. This is, in substance, a reverse-merger listing vehicle: Scancell gains a pre-existing Nasdaq shell rather than a complementary pipeline, while Neuphoria stockholders keep exposure to their own assets via CVRs. It is a well-trodden route for small-cap biotechs seeking US capital access without a traditional IPO, explaining why it is paired so tightly with an $89 million raise rather than framed as a scientific combination.
The more consequential news for shareholders arguably came three months earlier. FDA Fast Track designation, awarded for iSCIB1+ on 28 April 2026, brings eligibility for rolling review, priority review and Accelerated Approval , plus more frequent regulatory engagement — all of which can shorten the path to market for a company that has spent over two decades in development.
Latest Financial and Operational Performance
Scancell's half-year results, published 29 January 2026, showed cash of £8.6 million at 31 October 2025, topped up by £3.0 million of R&D tax credits received that December. Management described this as providing cash runway "to H2 2026, beyond near-term clinical and regulatory milestones" — underlining why the July financing was needed to carry the company through a Phase 3 trial running into 2028.
The six-month operating loss narrowed to £8.9 million from £10.5 million a year earlier, and the loss after tax fell to £5.7 million from £12.5 million, aided by the tax Credit and lower spend. R&D expenditure dropped to £6.1 million from £8.0 million as Manufacturing costs eased after a scaled GMP production batch for iSCIB1+ was completed.
Key Numbers
- FDA Fast Track designation for iSCIB1+ granted 28 April 2026
- Merger and financing agreement with Neuphoria Therapeutics (Nasdaq: NEUP) announced 23 July 2026
- Financing of up to $89 million, including a $39.1 million private placement and up to $25 million debt Facility (BlackRock term sheet)
- New shares placed at $0.1205 (9p) each
- Pro forma split roughly 85.5% Scancell / 14.5% Neuphoria shareholders before new financing
- Cash of £8.6 million at 31 October 2025, plus £3.0 million R&D tax credit received December 2025
- H1 FY26 operating loss £8.9 million (down from £10.5 million); loss after tax £5.7 million (down from £12.5 million)
- Phase 2 SCOPE trial: 74–77% PFS at 16–20 months in the target HLA population, against roughly 43–50% for standard-of-care checkpoint inhibitors alone
Growth Opportunities
The clinical case rests on repeated Phase 2 SCOPE updates. Data disclosed 9 December 2025 showed 74% progression-free survival at 16 months in patients with specific HLA alleles (roughly 80% of melanoma patients), against 50% at 11.5 months for standard-of-care ipilimumab plus nivolumab — a 24-point gap. By the April 2026 Fast Track announcement, the company reported 77% PFS at 20 months combined with checkpoint inhibitors, versus 43% for checkpoint inhibitors alone. The FDA cleared an IND for a global, registrational Phase 3 trial on 26 January 2026, targeted to start H2 2026 with a primary readout in H2 2028. Beyond melanoma, Modi-1 is in the Phase 2 ModiFY trial across head and neck and renal cell cancers, data due H1 2026, and GlyMab Subsidiary candidate SC134 has had positive early FDA and MHRA feedback.
Risks Investors Should Know
Scancell remains a pre-revenue company reliant on external funding, and the newly announced package, while substantial, is contingent on shareholder votes and other closing conditions. The Phase 3 trial carries the binary risk inherent to late-stage oncology — a positive Phase 2 signal does not guarantee success. The Neuphoria deal adds integration complexity, dilutes existing shareholders, and ties part of future value to CVRs whose worth depends on unrelated neuropsychiatric assets. Nasdaq Listing Rules bring further cost and disclosure obligations.
What to Watch Next
Watch for the shareholder votes ahead of the targeted late-Q4 2026 completion, confirmation of the Nasdaq listing, Modi-1 data due H1 2026, initiation of the global Phase 3 trial, and further PFS updates promised for H1 2027.
Outlook
Scancell's FDA Fast Track designation gave the clinical story fresh credibility; the Neuphoria merger is the mechanism designed to fund it. Whether it delivers a smooth route to Nasdaq and a fully financed Phase 3 programme, or adds complexity to an already binary clinical bet, will become clearer as the approvals and votes play out over the rest of 2026.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...